epelsiban: Clinical Trials

5 completed, 1 terminated, 1 withdrawn. 5 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	5	Completed 4, Terminated 1
Phase 2	2	Completed 1, Withdrawn 1

Follow epelsiban: new trials by email Literature Review of epelsiban trials Research Report on epelsiban

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Placebo-controlled Proof of Concept Study of Epelsiban in Women With Adenomyosis Epelsiban, Placebo - Adenomyosis	Phase 2	Withdrawn	GlaxoSmithKline		2016-07-01	2017-01-18
Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban Administered in Repeat Doses in Healthy Women Volunteers Epelsiban (GSK557296), Placebo to match GSK557296 - Embryo Transfer	Phase 1	Completed	GlaxoSmithKline	31	2015-07-09	2018-09-13
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Epelsiban in Healthy Female Volunteers Epelsiban - Embryo Transfer	Phase 1	Completed	GlaxoSmithKline	12	2014-12-18	2018-09-13
A Study to Evaluate Pharmacokinetics, Pharmacodynamics and Tissue Concentrations of Epelsiban Epelsiban, Placebo, Oxytocin - Embryo Transfer	Phase 1	Terminated	GlaxoSmithKline	33	2014-08-28	2017-05-08
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of GSK557296 in Healthy Women Volunteers After Single and Repeat Dosing GSK557296 10 mg, GSK557296 150 mg, GSK557296 dose 3 - Embryo Transfer	Phase 1	Completed	GlaxoSmithKline	36	2012-08-16	2017-06-07
A Study To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two Oral Doses of GSK557296 in a Study in Men With Premature Ejaculation GSK557296, placebo - Premature Ejaculation	Phase 2	Completed	GlaxoSmithKline	77	2009-12-23	2017-09-12
A First Time in Human Study in Healthy Male Volunteers for Compound GSK557296. GSK557296 - Obstetric Labour, Premature, Premature Ejaculation	Phase 1	Completed	GlaxoSmithKline	42	2007-10-01	2012-03-19

Conditions studied

Premature Ejaculation (2)  ·  Adenomyosis (1)  ·  Menorrhagia (1)  ·  Premature Birth (1)

Sponsors

GlaxoSmithKline (7)

Countries

United States (7)  ·  Netherlands (1)

Results publications

PMID 28556598, PMID 23937679, PMID 27137713